Shares of Concordia Healthcare Corp. (NASDAQ:CXRX) fell 4.9% on Wednesday . The stock traded as low as $19.57 and last traded at $20.02, with a volume of 155,870 shares changing hands. The stock had previously closed at $21.06.

Several research firms have weighed in on CXRX. Canaccord Genuity reissued a “buy” rating on shares of Concordia Healthcare Corp. in a report on Sunday, June 26th. CIBC upped their target price on Concordia Healthcare Corp. from $31.00 to $34.00 and gave the company a “sector performer” rating in a report on Tuesday, March 29th. TD Securities lowered their target price on Concordia Healthcare Corp. from $48.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, March 25th. Royal Bank Of Canada reissued an “outperform” rating and issued a $73.00 target price on shares of Concordia Healthcare Corp. in a report on Thursday, May 26th. Finally, Zacks Investment Research lowered Concordia Healthcare Corp. from a “hold” rating to a “sell” rating in a report on Monday, April 18th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Concordia Healthcare Corp. presently has an average rating of “Buy” and a consensus target price of $52.35.

The firm’s market cap is $1.02 billion. The firm has a 50-day moving average of $25.75 and a 200-day moving average of $28.68.

Concordia Healthcare Corp. (NASDAQ:CXRX) last issued its quarterly earnings results on Friday, May 13th. The company reported $1.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.54 by $0.19. The company earned $228.50 million during the quarter, compared to analysts’ expectations of $231 million. The business’s revenue for the quarter was up 570.1% compared to the same quarter last year. Analysts predict that Concordia Healthcare Corp. will post $6.11 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, July 15th will be paid a dividend of $0.075 per share. The ex-dividend date of this dividend is Wednesday, July 13th. This represents a $0.30 annualized dividend and a yield of 1.50%.

A number of institutional investors have recently modified their holdings of the stock. Diamond Hill Capital Management Inc. raised its position in shares of Concordia Healthcare Corp. by 294.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 850,645 shares of the company’s stock valued at $34,732,000 after buying an additional 634,880 shares in the last quarter. Morgan Stanley raised its stake in Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock valued at $11,015,000 after buying an additional 53,305 shares in the last quarter. Thornburg Investment Management Inc. raised its stake in Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock valued at $4,746,000 after buying an additional 37,847 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Concordia Healthcare Corp. during the fourth quarter valued at $2,419,000. Finally, ProShare Advisors LLC bought a new stake in Concordia Healthcare Corp. during the fourth quarter valued at $1,671,000.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.